Cargando…

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer

In estrogen receptor (ER)-positive breast cancer, changes in biomarker expression after neoadjuvant therapy indicate the therapeutic response and are prognostic. However, there is limited information about the biomarker alteration caused by neoadjuvant endocrine therapy in ER-positive and human epid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Mengping, You, Chong, Song, Qianqian, Hu, Lina X. J., Guo, Zhaorong, Yao, Qian, Hou, Wei, Sun, Wei, Liang, Baosheng, Zhou, Xiao-Hua, Liu, Yiqiang, Hu, Taobo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866043/ https://www.ncbi.nlm.nih.gov/pubmed/36676023 http://dx.doi.org/10.3390/life13010074

Ejemplares similares

AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status
por: Long, Mengping, et al.
Publicado: (2022)

Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy
por: Hu, Taobo, et al.
Publicado: (2022)

A Histone Acetylation Modulator Gene Signature for Classification and Prognosis of Breast Cancer
por: Long, Mengping, et al.
Publicado: (2021)

Intraparenchymal breast leiomyoma and atypical leiomyoma
por: Long, Mengping, et al.
Publicado: (2022)

A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes
por: Hu, Taobo, et al.
Publicado: (2021)

Two-Dose Vaccination Significantly Prolongs the Duration from Symptom Onset to Death: A Retrospective Study Based on 173,894 SARS-CoV-2 Cases in Khyber Pakhtunkhwa, Pakistan
por: Song, Qianqian, et al.
Publicado: (2022)

Mechanism and effect of stress granule formation in cancer and its potential roles in breast cancer therapy
por: Hu, Taobo, et al.
Publicado: (2021)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Yixi, et al.
Publicado: (2022)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

Tripartite genome of all species
por: Long, MengPing, et al.
Publicado: (2016)

The natural history of breast cancer: a chronological analysis of breast cancer progression using data from the SEER database
por: Wu, Jinbo, et al.
Publicado: (2022)

BM-Net: CNN-Based MobileNet-V3 and Bilinear Structure for Breast Cancer Detection in Whole Slide Images
por: Huang, Jin, et al.
Publicado: (2022)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Biomarker Genes for Detecting Estrogenic Activity of Endocrine Disruptors via Estrogen Receptors
por: Jung, Eui-Man, et al.
Publicado: (2012)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
por: Chen, Hai-long, et al.
Publicado: (2023)

Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
por: Cao, Lifen, et al.
Publicado: (2021)

Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes
por: Lizcano, Fernando
Publicado: (2022)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

ENDOCRINE DISRUPTORS: Estrogens in a Bottle?
por: Barrett, Julia R.
Publicado: (2009)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-FES PET
por: Xie, Yizhao, et al.
Publicado: (2022)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration
por: Zhou, Xingchen, et al.
Publicado: (2015)

Endocrine disrupting chemicals differentially alter intranuclear dynamics and transcriptional activation of estrogen receptor-α
por: Bolt, Michael J., et al.
Publicado: (2021)

Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells
por: Karakas, Bahriye, et al.
Publicado: (2021)

The Endocrine Role of Estrogens on Human Male Skeleton
por: Rochira, Vincenzo, et al.
Publicado: (2015)

Non-canonical Estrogen Signaling in Endocrine Resistance
por: Ranganathan, Prathibha, et al.
Publicado: (2019)

Neoadjuvant chemotherapy alters peripheral and tumour‐infiltrating immune cells in breast cancer revealed by single‐cell RNA sequencing
por: Zhou, Hanlin, et al.
Publicado: (2021)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

In utero estrogenic endocrine disruption alters the stroma to increase extracellular matrix density and mammary gland stiffness
por: Wormsbaecher, Clarissa, et al.
Publicado: (2020)

2,4-Dichlorophenol Shows Estrogenic Endocrine Disruptor Activity by Altering Male Rat Sexual Behavior
por: Ferris Pasquini, Veronica, et al.
Publicado: (2023)

Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines
por: Madigan, Lauren I., et al.
Publicado: (2020)

The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer
por: Isnaldi, Edoardo, et al.
Publicado: (2022)

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
por: Madeira, Marcelo, et al.
Publicado: (2013)

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
por: Chia, Y H, et al.
Publicado: (2010)

Problems for risk assessment of endocrine-active estrogenic compounds.
por: Safe, Stephen H, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_9nbp0l6ta92310kgfelmidvhq0